<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347187</url>
  </required_header>
  <id_info>
    <org_study_id>REGATTA203121975</org_study_id>
    <nct_id>NCT04347187</nct_id>
  </id_info>
  <brief_title>REGistry of Long-term AnTithrombotic TherApy-2</brief_title>
  <acronym>REGATTA-2</acronym>
  <official_title>Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic
      therapy in patients with atrial fibrillation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The register is a Russian prospective single-center observational study of patients who have
      indications for long-term antithrombotic therapy in connection with atrial fibrillation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>composite of major cardiovascular events</measure>
    <time_frame>unclusion up to 5 years</time_frame>
    <description>stroke, myocardial infarction, stent thrombosis [definite or probable], or urgent revascularization, cqrdiac death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>composite of any bleeding events</measure>
    <time_frame>unclusion up to 5 years</time_frame>
    <description>major, clinically relevant nonmajor, minor (BARC, ISTH,GARFIELD AF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mutations in following genes</measure>
    <time_frame>inclusion</time_frame>
    <description>CYP2C9*, VKORC1</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulants</intervention_name>
    <description>oral anticoagulants, dual or triple antithrombotic theraphy</description>
    <other_name>antiplatelets</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, white cells, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized or outpatients with confirmed atrial fibrillation and CHA2DS2VASC &gt; 1
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented atrial fibrillation with CHA2DS2VASC &gt; 1

        Exclusion Criteria:

          -  Subjects who are unwilling or unable to provide informed consent. ACS within 12 months
             before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe
             liver or muscle disease Severe kidney disease / renal failure with creatinine &gt; 3
             mg/dl Conceivable impossibility to come in touch with the patient or his family at
             1-year after the intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizaveta Panchenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ekaterina Kropacheva, PhD</last_name>
    <phone>+79166760695</phone>
    <email>katekrab@list.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elizaveta Panchenko, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ekaterina Kropacheva, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oksana Zemlyanskaya, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>van Rein N, Heide-Jørgensen U, Lijfering WM, Dekkers OM, Sørensen HT, Cannegieter SC. Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation. 2019 Feb 5;139(6):775-786. doi: 10.1161/CIRCULATIONAHA.118.036248.</citation>
    <PMID>30586754</PMID>
  </reference>
  <reference>
    <citation>Schjerning Olsen AM, McGettigan P, Gerds TA, Fosbøl EL, Olesen JB, Sindet-Pedersen C, Staerk L, Hansen ML, Pallisgaard JL, Køber L, Torp-Pedersen C, Gislason GH, Lamberts M. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. Eur Heart J Cardiovasc Pharmacother. 2019 Nov 19. pii: pvz069. doi: 10.1093/ehjcvp/pvz069. [Epub ahead of print]</citation>
    <PMID>31742339</PMID>
  </reference>
  <reference>
    <citation>Panchenko E, Kropacheva E, Dobrovolsky A, Titaeva E, Zemlyanskaya O, Trofimov D, Galkina I, Lifshits G, Vereina N, Sinitsin S, Vorobyeva N, Grehova L, Zateyshchikov D, Zotova I, Vavilova T, Sirotkina O, Grontkovskaya A. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients. Pharmacogenomics J. 2020 Feb 6. doi: 10.1038/s41397-020-0157-2. [Epub ahead of print]</citation>
    <PMID>32024944</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</investigator_affiliation>
    <investigator_full_name>Elizaveta Panchenko</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation, coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the article after deidentification (text, tables, figures)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following publication</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal . For individual participant data meta-analysis.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

